1. Home
  2. AKBA vs MSEX Comparison

AKBA vs MSEX Comparison

Compare AKBA & MSEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • MSEX
  • Stock Information
  • Founded
  • AKBA 2007
  • MSEX 1897
  • Country
  • AKBA United States
  • MSEX United States
  • Employees
  • AKBA N/A
  • MSEX N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • MSEX Water Supply
  • Sector
  • AKBA Health Care
  • MSEX Utilities
  • Exchange
  • AKBA Nasdaq
  • MSEX Nasdaq
  • Market Cap
  • AKBA 958.6M
  • MSEX 1.1B
  • IPO Year
  • AKBA 2014
  • MSEX N/A
  • Fundamental
  • Price
  • AKBA $3.66
  • MSEX $54.12
  • Analyst Decision
  • AKBA Strong Buy
  • MSEX Buy
  • Analyst Count
  • AKBA 5
  • MSEX 4
  • Target Price
  • AKBA $6.90
  • MSEX $61.00
  • AVG Volume (30 Days)
  • AKBA 6.6M
  • MSEX 114.9K
  • Earning Date
  • AKBA 08-07-2025
  • MSEX 07-30-2025
  • Dividend Yield
  • AKBA N/A
  • MSEX 2.39%
  • EPS Growth
  • AKBA N/A
  • MSEX 18.33
  • EPS
  • AKBA N/A
  • MSEX 2.40
  • Revenue
  • AKBA $184,909,000.00
  • MSEX $195,654,000.00
  • Revenue This Year
  • AKBA $26.88
  • MSEX $9.16
  • Revenue Next Year
  • AKBA $44.34
  • MSEX $7.82
  • P/E Ratio
  • AKBA N/A
  • MSEX $23.67
  • Revenue Growth
  • AKBA N/A
  • MSEX 16.02
  • 52 Week Low
  • AKBA $0.80
  • MSEX $48.18
  • 52 Week High
  • AKBA $4.08
  • MSEX $70.73
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 63.96
  • MSEX 35.72
  • Support Level
  • AKBA $3.56
  • MSEX $54.29
  • Resistance Level
  • AKBA $3.87
  • MSEX $58.04
  • Average True Range (ATR)
  • AKBA 0.22
  • MSEX 1.34
  • MACD
  • AKBA -0.04
  • MSEX -0.06
  • Stochastic Oscillator
  • AKBA 36.53
  • MSEX 1.80

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About MSEX Middlesex Water Company

Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The firm operates in the eastern states of New Jersey, Delaware, and Pennsylvania. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.

Share on Social Networks: